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Abstract
Objective—Medicare claims can be useful in chemotherapy-related comparative effectiveness
research (CER) estimating survival, but methods for estimating patients’ treatment morbidity are
currently lacking. We sought to determine if patients’ health care use in the claims is a marker of
treatment morbidity.
Materials and Methods—For 249 elderly Medicare patients with breast or colon cancer who
were treated in two adjuvant clinical trials, we merged patients’ National Cancer Institute
Common Toxicity Criteria for Adverse Events (CTC AEs) trial data with their contemporaneous
Medicare claims. We estimated associations of patients’ grade ≥3 CTC AE counts and their use of
two types of hospital-based health care in claims (i.e., emergency room (ER) visits and
hospitalizations).
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Results—ER visits and hospitalizations were significantly positively associated with grade ≥3
CTC AE counts incurred by patients during the study. Eight percent of patients without any grade
≥3 CTC AEs had one or more hospitalizations during the observation period compared to 43% of
patients with three or more grade ≥3 CTC AEs (p < 0.01). Those who were hospitalized at least
once had more than three times the rate of grade ≥3 CTC AEs (IRR 3.70, 95% CI: 2.53–5.40)
compared to those who were not. With each hospitalization, the daily incidence rate of any grade
≥3 CTC AE more than doubled (IRR 2.10, 95% CI: 1.54–2.86).
Conclusions—Because hospitalization is strongly associated with clinically significant toxicity
it may be a useful outcome for Medicare claim-based CER comparing treatment morbidity for
elderly patients receiving different adjuvant chemotherapy regimens.
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1. Introduction
Medicare spends billions of dollars annually on chemotherapy for elderly patients with
cancer, but surprisingly little is known about the extent to which cancer chemotherapies help
or harm such elderly patients.1,2 This unsettling paradox is the direct result of the well-
described under-enrollment of elderly patients with cancer in clinical trials of
chemotherapy.3−5 The dearth of realistic estimates of chemotherapy-related survival and
toxicities hinders community oncologists as they discuss with elderly patients the risks and
benefits of chemotherapy use, compromising patient–physician decision-making.6,7
Population research using observational data sources for comparative effectiveness research
(CER) has the potential to yield estimates of the benefits and risks of treatment for patients
with cancer who are traditionally underrepresented in clinical trials. Overall survival is well
measured in Medicare data, but post-treatment morbidity is not. Some researchers have
posited that International Classification of Disease 9th Revision (ICD-9) diagnostic codes
provide valid estimates of post-treatment toxicities affecting elderly usual care patients.8–15
Other research suggests that this is not the case; we found that Medicare ICD-9 diagnostic
and procedure codes were poor measures of the common and clinically significant toxicities
classified as grade ≥3 Common Terminology Criteria for Adverse Events (CTC AEs), a
gold-standard measure of toxicity.16 This finding motivated our search for alternative
indicators of severe morbidity in elderly patients with cancer who are receiving
chemotherapy (i.e., intercurrent morbidity) using Medicare data. Were reliable methods
developed, such morbidity could be studied as a salient endpoint in Medicare-based CER.
We chose to study hospital-based health care use under Medicare because it is (1) a
clinically meaningful measure of severity of illness (i.e., lesser illnesses can be treated in the
outpatient setting), (2) something most elderly patients wish to avoid,17,18 (3) a risk factor
for iatrogenic processes including life-threatening infections,19 (4) a risk factor for
functional decline,20 (5) easily measured in Medicare data, and (6) being used empirically in
Medicare-based CER of adjuvant chemotherapy regimens as a measure of treatment-related
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toxicity.21 Specifically, we assess elderly Medicare patients treated on two adjuvant
chemotherapy trials for breast and colon cancer and evaluate for associations between the
burden of CTC AEs they incurred while in the clinical trials and the amount of hospital-
based health care they used during the same period. We hypothesized a positive association
between standard clinical trial metrics of treatment toxicity and hospital-based health care
use during the clinical trial period.
2. Methods
2.1. Data and Cohorts
2.1.1. CALGB Data—We used clinical trial data from the Cancer and Leukemia Group B
(CALGB) to identify elderly clinical trial patients treated in the experimental setting with
standard first-line adjuvant chemotherapy on CALGB breast and colon cancer trials
(CALGB 49907 and 89803).22,23 The CALGB, now a part of the Alliance for Clinical Trials
in Oncology, was an NCI-sponsored cooperative oncology research group representing a
network of over 3000 physicians from 29 academic medical centers and 225 community
hospitals. Members of multi-modality treatment programs in seven disease areas developed
therapeutic trials, which were opened for patient accrual at CALGB institutions. Data from
trials are maintained centrally. Registration variables common to all therapeutic trials
include study number, subject identifiers, demographic and disease information, treatment
information (e.g., drugs administered, dates of treatment, CTC AE information) and survival
endpoints.
The CTC AE is the standard metric of chemotherapy-related toxicity used in clinical trials
nationally. The taxonomy requires identification of a category of toxicity and within the
category a numeric grade of severity of the toxicity, ranging from 1 (mild toxicity) to 5
(death).24 CTC AEs graded 3 or higher are considered clinically important and for this
reason reports of clinical trial results usually include the proportion of patients with grade ≥3
CTC AEs by type (e.g., neutropenia or diarrhea).
2.1.2. Medicare Data—Medicare is a federally sponsored health insurance program
administered by the Centers for Medicare and Medicaid Services (CMS) whose beneficiaries
include more than 96% of all US citizens aged 65 and older.25 CMS maintains billing
records of outpatient, inpatient, home health, hospice, durable medical equipment, and other
claims for all beneficiaries not enrolled in risk contract health maintenance organizations
(HMOs). Of note, Medicare reimburses providers for costs associated with clinical trials
including those of drugs and drug combinations that have been previously established to be
standards of care. All regimens we studied were standard chemotherapy regimens at the time
of trial enrollment.
2.1.3. Cohort Construction—We identified all study subjects who enrolled in the
standard arm of CALGB 49907 or either the standard or experimental arm of 89803.
CALGB 49907 studied women aged 65 and older with loco-regional breast cancer who were
randomized to post-operative adjuvant chemotherapy with one of two standard
chemotherapy regimens (i.e., the combination of doxorubicin and cyclophosphamide or the
combination of cyclophosphamide, methotrexate, and fluorouracil) vs. the experimental arm
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(i.e., oral capecitabine). We study only patients treated on the standard arm as capecitabine
is not reliably measured in claims.22 CALGB 89803 studied patients with loco-regional
colon cancer who were randomized to post-operative adjuvant chemotherapy with standard
fluorouracil and leucovorin vs. fluorouracil, leucovorin, and irinotecan.23 The Appendix
(page 2) contains a detailed description of patient eligibility for each trial. For the 479
CALGB patients who were (1) Medicare eligible based on age and (2) treated at centers that
were reimbursed by Medicare, we were able to match 406 (85%) to CMS Medicare claims
files from the corresponding calendar period using Social Security numbers. The linked data
set contained both CALGB clinical trial data (e.g., demographic information, study arm, and
CTC AE information) and Medicare data. Elderly CALGB patients who did not match to
Medicare data were more likely to have been treated in the breast trial and be female (see
Appendix page 3). Among the 406 patients, 98 were excluded because they were enrolled in
HMOs for which claims data are unavailable. Patients enrolled in HMOs were more likely to
be male, treated in the colon trial, and be younger than patients not enrolled in HMOs (see
Appendix, page 4). An additional 46 patients were excluded because they were not
continuously eligible for Medicare parts A and B during the observation period. Under both
the latter conditions, patients’ health care use may be incompletely observed leading to
biased estimates of hospital-based health care use. We excluded 13 patients because of
incomplete information regarding the observation period. The final analytic sample
consisted of 249 elderly Medicare patients treated in one of the two CALGB adjuvant
chemotherapy trials. We chose to study patients with breast or colorectal cancer who were
receiving adjuvant chemotherapy because these patients might reasonably be expected to use
hospital-based health care during the clinical trial for chemotherapy-related toxicity
management. That is, to be eligible for treatment in the trial, the patients had to have fully
recovered from their curative-intent cancer surgery; this implied that their gross tumor had
been removed, leaving only microscopic disease. For patients with micro-metastatic disease
who are receiving adjuvant chemotherapy, hospitalizations would be expected to more often
be chemotherapy-related toxicity rather than primarily related to their tumor (e.g., post-
operative complications and/or progressive cancer).
The observation period was patient-specific and bounded (inclusively) by the date of first
treatment with clinical trial therapy through 30 days following the date of last treatment with
the same therapy, as ascertained from Medicare claims.
2.1.4. Outcome Variables—The key outcome variable was the number of grade ≥3 CTC
AEs experienced by each patient during the observation period. Patient demographic and
disease attributes were obtained from CALGB and CMS data.
2.1.5. Predictor Variables—The key predictor variables came from the MEDPAR file
and were counts of the following types of hospital-based health care utilization incurred
during the study period: ER visits, hospitalizations, and days in hospital. The former two
variables were also transformed into binary variables indicating at least one incident of each
type. If patients were admitted to the hospital through the ER, we counted only the
hospitalization. Thus ER visits were necessarily self-limited hospital-based health care
encounters. Covariates were patient age, sex, race, Eastern Cooperative Oncology Group
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(ECOG) performance status (PS), Charlson comorbidity score (CCS) and neighborhood
poverty. Additionally, we adjusted for the season during which treatment was initiated (i.e.,
winter, spring, summer, or fall).
2.1.6. Statistical Analyses—To assess the hypothesis that hospital-based health care use
might function as an indicator of toxicities in subsequent CER, we modeled AEs as the
outcomes of interest and hospital-based health care use as the predictors. We tested
associations between covariates and outcomes using chi-square tests for categorical
predictors and t-tests for continuous variables. For each treatment arm, we also described the
association between number of hospital-based events and number of AEs with Spearman
correlation coefficients. We described multivariate associations between counts of patient
grade ≥3 CTC AEs and use of any of the two types of hospital-based health care studied
with negative binomial log-linear regressions. Negative binomial log-linear regression also
described multivariate associations between count of patient grade ≥3 CTC AEs and
episodes of the two types of hospital-based health care incurred during the study period as
well as days in hospital. Because time on treatment for clinical trials was not uniform across
patients, we adjusted the models for the observation period. The observation period was
patient-specific and bounded (inclusively) by the date of first treatment with clinical trial
therapy through 30 days following the date of last treatment with the same therapy. The
natural log of this number was included as a predictor to account for non-uniformity of the
observation period. Additionally, because patients were treated at a fixed number of treating
facilities, we adjusted the standard errors of the estimates for the clustering of multiple
patients within single treating facilities.
Finally, in an additional set of analyses, we studied the patients treated in the adjuvant colon
cancer trial (i.e., CALGB 89803), to determine whether covariates modified the association
between hospitalization and the incidence rate of AEs. We tested interactions of each
covariate with hospitalization. These included the treatment arm to which the patients were
randomized as well as by other salient patient attributes including demographics, area
poverty, and seasonality. To do this, we investigated separate models that included
hospitalization and patient attribute interaction terms. In compliance with our data use
agreement with Medicare, we have suppressed those results where Medicare variables have
cell sizes <11. This research was approved by Duke University’s, Harvard Medical
School’s, and Massachusetts General Hospital’s institutional review boards and conducted
in compliance with their regulations.
3. Results
The cohorts’ characteristics and hospital-based health care utilization are described in Table
1. More than 50% of patients experienced at least one clinically significant toxicity (i.e.,
CTC AE grade ≥3) but none experienced grade 5 toxicity (i.e., death). For patients with at
least one CTC AE grade ≥3, the median numbers of distinct toxicity categories and events
were both 2. Table 2 contains results of bivariate analyses of predictor and outcome
variables. Patients who were treated in the colon cancer trials, those with higher ECOG
scores (indicating poorer performance status), greater comorbid illness, who lived in areas
with increased poverty, and any grade ≥3 CTC AEs were all more likely than others to be
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hospitalized during the trial. There was a positive association between the number of
episodes grade ≥3 CTC AEs and each of the three types of hospital-based health care use we
studied (i.e., ER use, hospitalizations, and hospital days). For example, 8% of patients
without any grade ≥3 CTC AEs had at least one hospital admission during the observation
period compared to 43% of patients with three or more grade ≥3 CTC AEs (p < 0.01). Fig. 1
shows the monotonically increasing relationship of the number of ER visits, hospitalizations,
and days in hospital with counts of grade ≥3 CTC AEs ranging from none to three or more.
Table 3 describes the correlation between the number of grade ≥3 CTC AEs that patients
experienced and the amount of each type of hospital-based health care they used during the
study. Hospitalization and hospital days appear to be more strongly correlated with patient
toxicity than ER visits. Table 4 contains results of adjusted negative binomial log-linear
regressions, showing positive clinically and statistically significant associations between the
number of patients’ grade ≥3 CTC AEs incurred and the amount of each of the two types of
hospital-based care they used (i.e., ER visits and hospitalizations) as well as the number of
days in hospital. In these results, again, the coefficients on the variables indicating
hospitalization (rather than ER visits) are more strongly associated with toxicity, though
95% confidence intervals do overlap for ER visits and hospitalizations. For example with
each hospitalization, patients’ daily incidence rate of grade ≥3 CTC AEs doubled (incidence
ratio rate [IRR] 2.10, 95% CI: 1.54–2.86) while adjusting for age, sex, race, comorbidity,
ECOG PS, tumor site, neighborhood poverty, and season of the year. As shown in Table 5,
those patients who were hospitalized at least once had nearly four times the rate of grade ≥3
CTC AEs (IRR 3.70, 95% CI: 2.53–5.40) compared to those who were not. Table 5 contains
results of adjusted negative binomial log-linear regressions, showing positive clinically and
statistically significant associations between the number of patients’ grade ≥3 CTC AEs
incurred and at least one patient hospitalization during the study period. In these results, the
daily incident rate for CTC AEs ≥3 increased by 3.70 (95% CI: 2.53–5.40) for patients who
experienced at least one hospitalization during the study period. Adjusted incidence of
toxicity was lower on the adjuvant colon trial than in the adjuvant breast cancer trial (IRR
0.54, 95% CI: 0.35–0.81) and adjusted incidence of toxicity was higher for those treated in
the summer relative to the winter season (IRR 2.72, 95% CI: 1.66–4.46). Table 6 contains
the results of a subset analysis through which we evaluated whether there was a treatment
arm by hospitalization interaction associated with toxicity for patients treated in the colon
cancer trial. Those patients who were hospitalized at least once had more than seven times
the rate of grade ≥3 CTC AEs (IRR 7.10, 95% CI: 4.12–12.22) compared to those who were
not. The estimated covariate effects are generally consistent with those in Table 5.
4. Discussion
For elderly Medicare beneficiaries with breast or colon cancer who were treated in two
adjuvant chemotherapy trials, gold-standard clinical trial measures of toxicity were strongly
associated with hospital-based health care utilization during the treatment period, with
hospitalization itself potentially the strongest predictor. This suggests that hospitalizations
documented in Medicare claims may be markers of intercurrent treatment toxicity in the
adjuvant chemotherapy setting for elderly patients with breast or colon cancer. These results
are important for at least three reasons. First, these findings may accelerate CER directed at
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estimating the risks as well as benefits of specific chemotherapy agents in the elderly
through identification of a clinically salient morbidity endpoint, hospitalization, that is easily
measured through the population-based CMS data. The additional information may be of
importance to patients and physicians choosing among chemotherapy regimens. Second,
these findings may be useful to health policy makers concerned about hospitalizations, the
single largest component of Medicare spending for elderly patients with cancer.26 Third,
measurement of post-treatment health care burden may provide insight as to the
generalizability of toxicity estimates that emanate from practice-shaping clinical trials in
which the elderly are often under-represented.
Among the limitations to our work are concerns regarding generalizability of our approach
to observational CER. Applying methods used in clinical trials to the observational setting
can be analytically challenging because, unlike the trial patients we studied, patients in the
usual care setting (i.e., observational setting) are not randomized to their treatments so that
both observable and unobservable features related to patients, providers, and other sources
may confound apparent associations between treatments and outcomes. For example, in the
clinical trial breast cohort, though patients’ age was representative of usual care patients
treated in the community, patients were on average slightly older than the usual care setting,
never male, and the percentage of white patients was higher than in the usual care
setting.27,28 In the clinical trial colon cancer cohort, patients were on average two years
younger than in the usual care setting and more often men, but the percentage of white
patients was similar to the usual care setting.29 These findings underscore the fact that our
results are applicable to trial-eligible recipients of adjuvant chemotherapy age 65 or older
and then only while they are receiving treatment through 30 days afterward.
Fortunately, concerns about confounding in the study of observational data and associated
CER are not new. In fact, they have led over thirty years to the genesis of rigorous analytic
methods intended to attenuate confounding in CER, acknowledging that it is not always
feasible or ethical to undertake randomized controlled trials yet information regarding
expected outcomes of therapies is needed by decision-makers (e.g., patients, their
physicians).30–35
In conclusion, hospital-based health care use may be a useful outcome in CER intended to
estimate differences in the risk of morbidity of specific treatments rendered in the usual care
setting. Among the types of hospital-based health care use studied, hospitalization itself had
the strongest association with the clinical trial toxicity measure and thus may be a salient
outcome for CER that seeks to compare the post-treatment morbidity of specific adjuvant
chemotherapy regimens.
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Trial patients’ use of hospital-based health care by grade ≥3 CTCAE treatment burden.
Legend: Bar graph showing monotonically increasing relationship of the number of ER
visits, hospitalizations, and days in hospital with counts of grade ≥3 CTC AEs ranging from
none to three or more. ER = emergency room; CTC AEs = Common Toxicity Criteria for
Adverse Events.
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Table 1
Attributes of elderly medicare patients treated on two CALGB adjuvant chemotherapy trials and their










  65–69 25% 36% 29%
  70–74 40% 39% 39%
  >75 35% 25% 32%
Sex
  Female 100.0% 39% 78%
  Male 00.0% 61% 22%
Race
  White 88% 92% 89%
  Black NR NR NR
  Other NR NR NR
ECOG PS
  0 73% 64% 70%
  1 26% 34% 29%
  2 1% 2% 1%
Mean Charlson Comorbidity Score (range) 0.86 (0–4) 0.62 (0–4) 0.77 (0–4)
Mean area poverty (% of residents in ZIP whose incomes are <federal poverty level)
Season of the year treatment started
10.5% 10.2% 10.4%
  Winter 28% 29% 28%
  Spring 26% 27% 26%
  Summer 21% 20% 21%
  Fall 25% 24% 25%
Days on treatment +30 days (median and range) 95 (30–212) 222 (30–338) 171
Any grade ≥3 CTC AE 66% 64% 65%
Count of episodes of ≥3 CTC AE (median and range) 2 (0–14) 1 (0–10) 1 (0–14)
Count of distinct categories of ≥3 CTC AE (median and range)
Any of the following:
1 (0–11) 1 (0–10) 1 (0–11)
  ER use 26% 26% 26%
  Hospitalization 20% 33% 25%
Median episodes/patient of hospital-based health care use (range)
  ER use 0 (0–3) 0 (0–4) 0 (0–4)
  Hospitalization 0 (0–2) 0 (0–6) 0 (0–6)
  Hospital days 0 (0–56) 0 (0–48) 0 (0–56)
Legend: ECOG PS = Eastern Cooperative Oncology Group performance status; CTC AE = Common Toxicity Criteria for Adverse Events; ER =
emergency room; NR = not reported as cell size too small.
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Table 3
Correlation between trial patient-level count of grade ≥3 CTC AEs and their hospital-based health care use






ER visits 0.27 <0.01
Hospitalizations 0.35 <0.01
Hospital days 0.34 <0.01
Legend: CTC AE = Common Terminology Criteria for Adverse Events; ER = emergency room.
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Table 4
Results of adjusted negative binomial log-linear regression models quantifying associations between number
of episodes of hospital-based health care and counts of grade ≥3 CTC AEs incurred by patients during the
study period (N = 249).
Variables IRR 95% CI
Amount of hospital-based health care
  Number of ER visits 1.61 1.32–1.96
  Number of hospitalizations 2.10 1.54–2.86
  Number of days in hospital 1.08 1.04–1.12
Legend: This table contains the results of negative binomial log-linear regressions measuring associations, at the patient-level, of episodes of grade
≥3 toxicities and episodes of hospital-based health care use during study period (i.e., date of first trial therapy through 30 days following last trial
therapy). The IRR is daily incidence rate ratio for grade ≥3 toxicity corresponding to a one unit increase in the specific type of health care use. The
analyses account for variation in the length of the number of days that the patients were observed and adjust standard errors to account for
clustering of patients within treatment centers. IRR = incidence rate ratio; CI = confidence interval.
Results are adjusted for patient age, sex, race, tumor site, Eastern Cooperative Oncology Group performance status, comorbidity, area poverty, and
seasonality.
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Table 5
Results of adjusted negative binomial log-linear regression models quantifying associations between
hospitalizations and grade ≥3 CTC AEs during the study period (N = 249).
Variables IRR 95% CI
Any hospitalization 3.70 2.53–5.40
Adjuvant trial
  Breast 1.00 Referent
  Colon 0.54 0.35–0.81
Age category
  65–69 1.00 Referent
  70–74 1.22 0.80–1.86
  >75 1.39 0.90–2.14
Sex
  Female 1.00 Referent
  Male 0.65 0.39–1.07
Race
  White 1.00 Referent
  Black 0.90 0.49–1.65
  Other 1.15 0.71–1.87
CS 1.09 0.90–1.33
ECOG PS
  0 1.00 Referent
  1 1.20 0.78–1.85
  2 0.62 0.24–1.58
ZIP poverty
  0–25% 1.00 Referent
  26–50% 0.73 0.46–1.16
  51–75% 1.06 0.65–1.75
  74–100% 0.87 0.47–1.62
Season
  Winter 1.00 Referent
  Spring 1.33 0.85–2.08
  Summer 2.72 1.66–4.46
  Fall 1.43 0.90–2.28
Legend: This table contains the results of negative binomial log-linear regressions expressing the rate of study patients experiencing a grade ≥3
toxicity during study period (i.e., date of first trial therapy through 30 days following last trial therapy) if they have at least one hospitalization
during the study period. The IRR is daily incidence rate ratio for grade >3 toxicity. The analyses account for variation in the length of the number
of days that the patients were observed and adjust standard errors to account for clustering of patients within treatment centers. IRR = incidence
rate ratio; CI = confidence interval.
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Table 6
Results of adjusted negative binomial log-linear regression models evaluating for treatment arm by
hospitalization interaction and incidence rate of grade ≥3 CTC AEs incurred by patients with colon cancer
during the study period (N = 90).
Variables IRR 95% CI
Any hospitalization 7.10 4.12–12.22
5FU/LV (control arm) 0.57 0.30–1.08
Any hospitalization × 5FU/LV (control arm) 0.72 0.33–1.59
Age category
  65–69 1.00 Referent
  70–74 1.24 0.55–2.78
  >75 2.43 1.26–4.69
Sex
  Female 1.00 Referent
  Male 0.33 0.16–0.68
Race
  White 1.00 Referent
  Black 0.47 0.09–2.36
  Other 2.40 0.93–6.15
CS 1.61 1.13–2.33
ECOG PS
  0 1.00 Referent
  1 1.69 0.88–3.23
  2 0.12 0.03–0.44
ZIP poverty
  0–25% 1.00 Referent
  26–50% 0.62 0.26–1.48
  51–75% 0.65 0.30–1.37
  74–100% 0.27 0.11–0.64
Season
  Winter 1.00 Referent
  Spring 1.92 1.04–3.53
  Summer 2.48 1.30–4.74
  Fall 1.88 1.12–3.16
Legend: This table contains the results of negative binomial log-linear regressions measuring associations, at the patient-level, of episodes of grade
≥3 toxicities and episodes of hospital-based health care use during study period (i.e., date of first trial therapy through 30 days following last trial
therapy). The IRR is daily incidence rate ratio for grade >3 toxicity. The analyses account for variation in the length of the number of days the
patients were observed and adjust standard errors to account for clustering of patients within treatment centers. IRR = incidence rate ratio; CI =
confidence interval.
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